Shanghai Yuzhihua Pharmaceutical Technology Development

Shanghai Yuzhihua Pharmaceutical Technology Development is a China-based biotechnology company focused on the research and development of innovative small molecule therapeutics. Founded in 2016 and headquartered in the Zhangjiang Hi-Tech Park in Shanghai, the company specializes in medicinal chemistry and drug design to address unmet medical needs in oncology. Their pipeline includes proprietary candidates such as YZH-2109, which has received IND approval and entered clinical trials for the treatment of advanced solid tumors. The firm leverages its expertise in molecular modeling and synthetic chemistry to develop high-potency, selective inhibitors. Shanghai Yuzhihua continues to advance its early-stage programs through the regulatory pipeline in China, targeting various cancer indications.